The expression level of Ecto-NTP diphosphohydrolase1/CD39 modulates exocytotic and ischemic release of neurotransmitters in a cellular model of sympathetic neurons

Journal of Pharmacology and Experimental Therapeutics

Volumn 337, Issue 2, 2011, Pages 524-532

  Corti, Federico ^a   Olson, Kim E ^a,b   Marcus, Aaron J ^a,b   Levi, Roberto ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; DOPAMINE; NERVE GROWTH FACTOR; RECOMBINANT CD39 ANTIGEN; RECOMBINANT ECTO NTP DIPHOSPHOHYDROLASE 1; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; AUTOCRINE EFFECT; BRAIN ISCHEMIA; CELL DIFFERENTIATION; CELL LEVEL; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG MECHANISM; EXOCYTOSIS; GENE DELETION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC RECOMBINATION; ISCHEMIA; MEMBRANE POLARIZATION AND DEPOLARIZATION; NONHUMAN; PRIORITY JOURNAL; RAT; SYMPATHETIC NERVE CELL;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTIGENS, CD; APYRASE; BLOTTING, WESTERN; DNA PRIMERS; DOPAMINE; EXOCYTOSIS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE SILENCING; ISCHEMIA; NERVE GROWTH FACTORS; NEURONS; NEUROTRANSMITTER AGENTS; NOREPINEPHRINE; PC12 CELLS; POTASSIUM; RATS; RECEPTORS, PURINERGIC P2X; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SYMPATHETIC NERVOUS SYSTEM;

EID: 79955041155     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.179994     Document Type: Article

References (54)

1. Arthur DB, Taupenot L, and Insel PA (2007) Nerve growth factor-stimulated neuronal differentiation induces changes in P2 receptor expression and nucleotidestimulated catecholamine release. J Neurochem 100:1257-1264.
2. + channel triggers transmitter release in PC12 cells. FEBS Lett 342:209-213.
3. Benedict CR, Shelton B, Johnstone DE, Francis G, Greenberg B, Konstam M, Probstfield JL, and Yusuf S (1996) Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators. Circulation 94:690-697. (Pubitemid 26289223)
4. Böhm M and Maack C (2000) Treatment of heart failure with β-blockers. Mechanisms and results. Basic Res Cardiol 95:15-24.
5. Bönisch H and Brüss M (2006) The norepinephrine transporter in physiology and disease. Handb Exp Pharmacol 175:485-524.
6. Burnstock G (2007) Physiology and pathophysiology of purinergic neurotransmission. Physiol Rev 87:659-797. (Pubitemid 47084682)
7. Burnstock G (2009) Autonomic neurotransmission: 60 years since sir Henry Dale. Annu Rev Pharmacol Toxicol 49:1-30.
8. Cao JM, Fishbein MC, Han JB, Lai WW, Lai AC, Wu TJ, Czer L, Wolf PL, Denton TA, Shintaku IP, et al. (2000) Relationship between regional cardiac hyperinnervation and ventricular arrhythmia. Circulation 101:1960-1969. (Pubitemid 30225278)
9. Chen PS, Chen LS, Cao JM, Sharifi B, Karagueuzian HS, and Fishbein MC (2001) Sympathetic nerve sprouting, electrical remodeling and the mechanisms of sudden cardiac death. Cardiovasc Res 50:409-416. (Pubitemid 32382168)
10. Clarke GL, Bhattacherjee A, Tague SE, Hasan W, and Smith PG (2010) β-Adrenoceptor blockers increase cardiac sympathetic innervation by inhibiting autoreceptor suppression of axon growth. J Neurosci 30:12446-12454.
11. Crack BE, Pollard CE, Beukers MW, Roberts SM, Hunt SF, Ingall AH, McKechnie KC, Ijzerman AP, and Leff P (1995) Pharmacological and biochemical analysis of FPL 67156, a novel, selective inhibitor of ecto-ATPase. Br J Pharmacol 114:475-481.
12. DiMaggio DA, Farah JM Jr, and Westfall TC (1994) Effects of differentiation on neuropeptide-Y receptors and responses in rat pheochromocytoma cells. Endocrinology 134:719-727. (Pubitemid 24057215)
13. Esler M (2000) The sympathetic system and hypertension. Am J Hypertens 13:99S-105S. (Pubitemid 30459894)
14. Esler M and Kaye D (2000) Measurement of sympathetic nervous system activity in heart failure: The role of norepinephrine kinetics. Heart Fail Rev 5:17-25. (Pubitemid 30301508)
15. Fabbro A, Skorinkin A, Grandolfo M, Nistri A, and Giniatullin R (2004) Quantal release of ATP from clusters of PC12 cells. J Physiol 560:505-517. (Pubitemid 39440111)
16. Fung CY, Marcus AJ, Broekman MJ, and Mahaut-Smith MP (2009) P2X(1) receptor inhibition and soluble CD39 administration as novel approaches to widen the cardiovascular therapeutic window. Trends Cardiovasc Med 19:1-5.
17. Gardner A, Westfall TC, and Macarthur H (2005) Endothelin-1-induced inhibition of ATP release from PC-12 cells is mediated by the ETB receptor: Differential response to endothelin-1 on ATP, neuropeptide Y, and dopamine levels. J Pharmacol Exp Ther 313:1109-1117. (Pubitemid 40731563)
18. Gayle RB 3rd, Maliszewski CR, Gimpel SD, Schoenborn MA, Caspary RG, Richards C, Brasel K, Price V, Drosopoulos JH, Islam N, et al. (1998) Inhibition of platelet function by recombinant soluble ecto-ADPase/CD39. J Clin Invest 101:1851-1859. (Pubitemid 28226103)
19. Grassi G, Seravalle G, Quarti-Trevano F, and Dell'oro R (2009) Sympathetic activation in congestive heart failure: Evidence, consequences and therapeutic implications. Curr Vasc Pharmacol 7:137-145.
20. Greene LA and Tischler AS (1976) Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc Natl Acad Sci USA 73:2424-2428.
21. Hasan W, Jama A, Donohue T, Wernli G, Onyszchuk G, Al-Hafez B, Bilgen M, and Smith PG (2006) Sympathetic hyperinnervation and inflammatory cell NGF synthesis following myocardial infarction in rats. Brain Res 1124:142-154. (Pubitemid 44779548)
22. Jarvis MF and Khakh BS (2009) ATP-gated P2X cation-channels. Neuropharmacology 56:208-215.
23. Joseph SM, Pifer MA, Przybylski RJ, and Dubyak GR (2004) Methylene ATP analogs as modulators of extracellular ATP metabolism and accumulation. Br J Pharmacol 142:1002-1014. (Pubitemid 39037050)
24. Julius S and Nesbitt S (1996) Sympathetic overactivity in hypertension. A moving target. Am J Hypertens 9:113S-120S.
25. Kittel A, Kiss AL, Müllner N, Matkó I, and Sperlágh B (2005) Expression of NTPDase1 and caveolins in human cardiovascular disease. Histochem Cell Biol 124:51-59. (Pubitemid 41253162)
26. Köhler D, Eckle T, Faigle M, Grenz A, Mittelbronn M, Laucher S, Hart ML, Robson SC, Müller CE, and Eltzschig HK (2007) CD39/ectonucleoside triphosphate diphosphohydrolase 1 provides myocardial protection during cardiac ischemia/ reperfusion injury. Circulation 116:1784-1794. (Pubitemid 350287103)
27. Koyama M, Seyedi N, Fung-Leung WP, Lovenberg TW, and Levi R (2003) Norepinephrine release from the ischemic heart is greatly enhanced in mice lacking histamine H3 receptors. Mol Pharmacol 63:378-382. (Pubitemid 36158373)
28. Kübler W and Strasser RH (1994) Signal transduction in myocardial ischaemia. Eur Heart J 15:437-445. (Pubitemid 24160689)
29. + channels. Eur J Neurosci 20:2917-2928. (Pubitemid 40007286)
30. Lindholm LH, Carlberg B, and Samuelsson O (2005) Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366:1545-1553. (Pubitemid 41540112)
31. Machida T, Heerdt PM, Reid AC, Schäfer U, Silver RB, Broekman MJ, Marcus AJ, and Levi R (2005) Ectonucleoside triphosphate diphosphohydrolase 1/CD39, local-ized in neurons of human and porcine heart, modulates ATP-induced norepinephrine exocytosis. J Pharmacol Exp Ther 313:570-577. (Pubitemid 40604156)
32. Marcus AJ, Broekman MJ, Drosopoulos JH, Islam N, Alyonycheva TN, Safier LB, Hajjar KA, Posnett DN, Schoenborn MA, Schooley KA, et al. (1997) The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39. J Clin Invest 99:1351-1360. (Pubitemid 27142773)
33. Marcus AJ, Broekman MJ, Drosopoulos JH, Islam N, Pinsky DJ, Sesti C, and Levi R (2003) Heterologous cell-cell interactions: Thromboregulation, cerebroprotection and cardioprotection by CD39 (NTPDase-1). J Thromb Haemost 1:2497-2509.
34. + channels. J Pharmacol Exp Ther 326:871-878.
35. Moskvina E, Unterberger U, and Boehm S (2003) Activity-dependent autocrineparacrine activation of neuronal P2Y receptors. J Neurosci 23:7479-7488. (Pubitemid 37034064)
36. North RA (2002) Molecular physiology of P2X receptors. Physiol Rev 82:1013-1067.
37. Petersson MJ, Rundqvist B, Johansson M, Eisenhofer G, Lambert G, Herlitz H, Jensen G, and Friberg P (2002) Increased cardiac sympathetic drive in renovascular hypertension. J Hypertens 20:1181-1187. (Pubitemid 34913638)
38. Pingle SC, Jajoo S, Mukherjea D, Sniderhan LF, Jhaveri KA, Marcuzzi A, Rybak LP, Maggirwar SB, and Ramkumar V (2007) Activation of the adenosine A1 receptor inhibits HIV-1 tat-induced apoptosis by reducing nuclear factor-B activation and inducible nitric-oxide synthase. Mol Pharmacol 72:856-867. (Pubitemid 47481409)
39. Schaefer U, Machida T, Broekman MJ, Marcus AJ, and Levi R (2007) Targeted deletion of ectonucleoside triphosphate diphosphohydrolase 1/CD39 leads to desensitization of pre-and postsynaptic purinergic P2 receptors. J Pharmacol Exp Ther 322:1269-1277. (Pubitemid 47295782)
40. Selwyn AP and Braunwald E (2001) Ischemic heart disease, in Harrison's Principles of Internal Medicine (Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, and Jameson JL eds) pp 1399-1410, McGraw-Hill, New York.
41. Sesti C, Broekman MJ, Drosopoulos JH, Islam N, Marcus AJ, and Levi R (2002) EctoNucleotidase in cardiac sympathetic nerve endings modulates ATPmediated feedback of norepinephrine release. J Pharmacol Exp Ther 300:605-611.
42. Sesti C, Koyama M, Broekman MJ, Marcus AJ, and Levi R (2003) Ectonucleotidase in sympathetic nerve endings modulates ATP and norepinephrine exocytosis in myocardial ischemia. J Pharmacol Exp Ther 306:238-244. (Pubitemid 36734378)
43. Seyedi N, Mackins CJ, Machida T, Reid AC, Silver RB, and Levi R (2005) Histamine H3-receptor-induced attenuation of norepinephrine exocytosis: A decreased protein kinase A activity mediates a reduction in intracellular calcium. J Pharmacol Exp Ther 312:272-280. (Pubitemid 40096478)
44. Taupenot L (2007) Analysis of regulated secretion using PC12 cells, in Current Protocols in Cell Biology (Bonifacino JS, Dasso M, Harford JB, Lippincott-Schwartz JB, Yamada KM, eds) chapter 15, unit 15.12, Wiley, New York.
45. Tiscornia G, Singer O, and Verma IM (2006) Production and purification of lentiviral vectors. Nat Protoc 1:241-245.
46. Vassort G (2001) Adenosine 5'-triphosphate: A P2-purinergic agonist in the myocardium. Physiol Rev 81:767-806. (Pubitemid 32273137)
47. Vollmayer P, Koch M, Braun N, Heine P, Servos J, Israr E, Kegel B, and Zimmermann H (2001) Multiple ecto-nucleotidases in PC12 cells: Identification and cellular distribution after heterologous expression. J Neurochem 78:1019-1028. (Pubitemid 32823151)
48. von Kügelgen I (2006) Pharmacological profiles of cloned mammalian P2Y-receptor subtypes. Pharmacol Ther 110:415-432.
49. Wang TF, Ou Y, and Guidotti G (1998) The transmembrane domains of ectoapyrase (CD39) affect its enzymatic activity and quaternary structure. J Biol Chem 273: 24814-24821. (Pubitemid 28454986)
50. Werner P, Seward EP, Buell GN, and North RA (1996) Domains of P2X receptors involved in desensitization. Proc Natl Acad Sci USA 93:15485-15490. (Pubitemid 27009625)
51. Westfall DP, Todorov LD, and Mihaylova-Todorova ST (2002) ATP as a cotransmitter in sympathetic nerves and its inactivation by releasable enzymes. J Pharmacol Exp Ther 303:439-444. (Pubitemid 35231212)
52. Yu JY, DeRuiter SL, and Turner DL (2002) RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. Proc Natl Acad Sci USA 99:6047-6052. (Pubitemid 34493262)
53. Zicha S, Tsuji Y, Shiroshita-Takeshita A, and Nattel S (2006) Beta-blockers as antiarrhythmic agents. Handb Exp Pharmacol 171:235-266.
54. Zimmermann H and Braun N (1999) Ecto-nucleotidases-molecular structures, catalytic properties, and functional roles in the nervous system. Prog Brain Res 120:371-385.